Our Company

Pipeline

Target ID

Hit to Lead

Lead Op

IND

Clinical trials

Best in class

First in class

Our first drug programme aims to generate a best-in-class asset to help millions of patients with neurological diseases.

Our second programme aims to generate a first-in-class asset to treat a universally fatal brain disease.

A science first company creating a step change in the way drugs are developed.

Lorem ipsum dolor sit amet consectetur. Pharetra phasellus suscipit dolor justo arcu a nibh volutpat ornare. Parturient at ridiculus turpis pharetra cras. Enim arcu ullamcorper massa in vel faucibus arcu. Turpis duis ullamcorper venenatis ut faucibus.

Amet proin sit mauris tellus feugiat viverra pretium nunc varius. Egestas interdum rhoncus quam vel ut. Elit mi netus nec ut turpis aliquam nisi.

Polly

Lorem ipsum dolor sit amet consectetur. Pharetra phasellus suscipit dolor justo arcu a nibh volutpat ornare. Parturient at ridiculus turpis pharetra cras.

Lauren

Hi Polly, what do you make of this issue?

Pipeline

Lorem ipsum dolor sit amet consectetur. Pharetra phasellus suscipit dolor justo arcu a nibh volutpat ornare. Parturient at ridiculus turpis pharetra cras. Enim arcu ullamcorper massa in vel faucibus arcu. Turpis duis ullamcorper venenatis ut faucibus.Amet proin sit mauris tellus feugiat viverra pretium nunc varius. Egestas interdum rhoncus quam vel ut. Elit mi netus nec ut turpis aliquam nisi.

London - Cambridge

Precision medicine through polymathic AI
‍

Contact us

Get in touch

Cosyne Therapeutics is a private limited company registered in England

Company number: 13171951

Registered Office: Medius House, 2 Sheraton Street, London W1F 8BH

VAT number GB: 385 9436 44

Our Company

Pipeline

London - Cambridge

Contact us

Follow us